LGND has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LGND has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Ligand Pharmaceuticals's total inventories for the quarter that ended in Dec. 2024 was $14.1 Mil. Ligand Pharmaceuticals's average total inventories from the quarter that ended in Sep. 2024 to the quarter that ended in Dec. 2024 was $13.8 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Ligand Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $9.46.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Ligand Pharmaceuticals's Days Inventory for the three months ended in Dec. 2024 was 443.13.
Inventory Turnover measures how fast the company turns over its inventory within a year. Ligand Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2024 was 0.21.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Ligand Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.32.
The historical data trend for Ligand Pharmaceuticals's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ligand Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Total Inventories | Get a 7-Day Free Trial |
![]() |
![]() |
26.49 | 27.33 | 13.29 | 23.97 | 14.11 |
Ligand Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Total Inventories | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
23.97 | 21.34 | 14.47 | 13.44 | 14.11 |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Ligand Pharmaceuticals (NAS:LGND) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Ligand Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is
Net-Net Working Capital Per Share (Q: Dec. 2024 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (256.165 | + | 0.75 * 38.376 | + | 0.5 * 14.114 | - | 111.335 |
- | 0 | - | 0) | / | 19.106 | ||
= | 9.46 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Ligand Pharmaceuticals's Days Inventory for the three months ended in Dec. 2024 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Dec. 2024 ) | / | Cost of Goods Sold (Q: Dec. 2024 ) | * | Days in Period |
= | 13.777 | / | 2.837 | * | 365 / 4 | |
= | 443.13 |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
Ligand Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Dec. 2024 ) | / | Average Total Inventories (Q: Dec. 2024 ) |
= | 2.837 | / | 13.777 | |
= | 0.21 |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ligand Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | 13.777 | / | 42.812 | |
= | 0.32 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Octavio Espinoza | officer: Chief Financial Officer | C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121 |
John L Lamattina | director | 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454 |
Andrew Reardon | officer: CHIEF LEGAL OFFICER & | C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121 |
Matthew E Korenberg | officer: VP, Finance and CFO | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Todd C Davis | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Nancy Ryan Gray | director | C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121 |
Stephen L Sabba | director | DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791 |
Martine Zimmermann | director | C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121 |
John W Kozarich | director | 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121 |
John L Higgins | officer: CEO & President | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Jason Haas | director | C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140 |
Matthew W Foehr | officer: EVP and COO | 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037 |
Jennifer R. Cochran | director | C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121 |
Charles S Berkman | officer: Asso. Gen. Counsel, Secretary | 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037 |
Sunil Patel | director | 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037 |
From GuruFocus
By GuruFocus News • 02-06-2025
By GuruFocus News • 11-06-2024
By GuruFocus News • 11-09-2024
By Marketwired • 02-25-2025
By Marketwired • 03-03-2025
By GuruFocus News • 02-27-2025
By GuruFocus News • 12-27-2024
By Business Wire • 11-01-2024
By GuruFocus News • 12-10-2024
By Marketwired • 02-27-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.